

●► **Avobis Bio**

(FDA, FTD)

The FDA grants Fast Track Designation to Avobis Bio for AVB-114 implantable cell therapy for Crohn's perianal fistulas

●► **Telix Pharmaceuticals**

(FDA , Priority review)

The FDA accepts Telix Pharmaceuticals' BLA of TLX250-CDx (Zircaix) for kidney cancer imaging and grants priority review

●► **Precigen, Inc.**

(FDA ,Priority review)

Precigen's BLA for PRGN-2012 has been granted FDA priority review in the treatment of adults with recurrent respiratory papillomatosis, with PDUFA target action date of August 27, 2025

●► **AbbVie + Gubra**

(Collabration)

AbbVie + Gubra sign license agreement to develop Amylin analog for obesity treatment



●► **Eli Lilly and Company**

(CHMP, Positive opinion)

Eli Lilly and Company has announced that the CHMP has issued a positive opinion for Jaypirca (pirtobrutinib) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have been previously treated with a BTK inhibitor

●► **Fosun Pharma**

(NMPA , Approval)

Fosun Pharma receives NMPA approval for Wan Ti Le (tenapanor hydrochloride tablets) for the control of serum phosphorus levels in dialysis patients with chronic kidney disease (CKD) who have an inadequate response or are intolerant to phosphorus binders

●► **IDEAYA Biosciences, Inc. + ATTMOS**

(Collabration)

IDEAYA Biosciences announced a research collaboration with ATTMOS to advance AI/ML-driven drug discovery for novel first-in-class oncology argetes

●► **Magnet Biomedicine + Lilly**

(Collabration)

Magnet Biomedicine collaborates and signs a license agreement with Lilly to discover and develop innovative molecular glue medicines

